Skip to Main Content

Paper Details

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Blood Cancer J
2
2023
Author NameAffiliation
Curtis A LachowiezThe University of Texas M.D. Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas M.D. Anderson Cancer Center
Gautam BorthakurThe University of Texas M.D. Anderson Cancer Center
Farhad RavandiThe University of Texas M.D. Anderson Cancer Center
Hagop KantarjianThe University of Texas M.D. Anderson Cancer Center
Courtney D DiNardoThe University of Texas M.D. Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2